Hemostemix Engages PatentVest to Strengthen its Global Patent Portfolio
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) has partnered with PatentVest, a subsidiary of MDB Capital, to strengthen its global patent portfolio in autologous stem cell therapy for cardiovascular diseases. PatentVest will provide comprehensive IP support including:
- Evaluation and optimization of existing patents
- Identification of new patentable therapeutic innovations
- Development of global filing strategies
- Enhancement of company value for strategic partnerships
PatentVest will accept partial payment in equity, aligning with shareholder interests. The partnership aims to extend patent terms based on ongoing FDA studies and leverage the company's automated bioreactor technology license to reduce production costs and improve treatment accessibility.
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ha stretto una collaborazione con PatentVest, una controllata di MDB Capital, per rafforzare il proprio portafoglio globale di brevetti nella terapia con cellule staminali autologhe per le malattie cardiovascolari. PatentVest fornirà un supporto completo in materia di proprietà intellettuale, che include:
- Valutazione e ottimizzazione dei brevetti esistenti
- Individuazione di nuove innovazioni terapeutiche brevettabili
- Sviluppo di strategie globali di deposito brevetti
- Incremento del valore aziendale per partnership strategiche
PatentVest accetterà un pagamento parziale in azioni, in linea con gli interessi degli azionisti. La partnership mira a estendere la durata dei brevetti sulla base degli studi FDA in corso e a sfruttare la licenza della tecnologia di bioreattore automatizzato dell’azienda per ridurre i costi di produzione e migliorare l’accessibilità ai trattamenti.
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) se ha asociado con PatentVest, una filial de MDB Capital, para fortalecer su cartera global de patentes en terapia con células madre autólogas para enfermedades cardiovasculares. PatentVest proporcionará un soporte integral en propiedad intelectual que incluye:
- Evaluación y optimización de las patentes existentes
- Identificación de nuevas innovaciones terapéuticas patentables
- Desarrollo de estrategias globales de presentación de patentes
- Incremento del valor de la empresa para alianzas estratégicas
PatentVest aceptará un pago parcial en acciones, alineándose con los intereses de los accionistas. La asociación busca extender los plazos de las patentes basándose en los estudios en curso de la FDA y aprovechar la licencia de la tecnología de biorreactor automatizado de la empresa para reducir costos de producción y mejorar el acceso a los tratamientos.
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF)는 MDB Capital의 자회사인 PatentVest와 협력하여 심혈관 질환을 위한 자가 줄기세포 치료 분야에서 글로벌 특허 포트폴리오를 강화합니다. PatentVest는 다음과 같은 포괄적인 지식재산권 지원을 제공합니다:
- 기존 특허 평가 및 최적화
- 새로운 특허 가능한 치료 혁신 발굴
- 글로벌 특허 출원 전략 개발
- 전략적 파트너십을 위한 기업 가치 향상
PatentVest는 주주 이익과 일치하도록 일부 대금을 주식으로 수령합니다. 이번 파트너십은 FDA 진행 중인 연구를 바탕으로 특허 기간 연장을 목표로 하며, 회사의 자동화 바이오리액터 기술 라이선스를 활용해 생산 비용을 절감하고 치료 접근성을 높이고자 합니다.
Hemostemix Inc. (TSXV : HEM) (OTCQB : HMTXF) s’est associé à PatentVest, une filiale de MDB Capital, afin de renforcer son portefeuille mondial de brevets dans le domaine de la thérapie par cellules souches autologues pour les maladies cardiovasculaires. PatentVest fournira un support complet en propriété intellectuelle incluant :
- Évaluation et optimisation des brevets existants
- Identification de nouvelles innovations thérapeutiques brevetables
- Développement de stratégies globales de dépôt de brevets
- Valorisation de l’entreprise pour des partenariats stratégiques
PatentVest acceptera un paiement partiel en actions, en accord avec les intérêts des actionnaires. Ce partenariat vise à prolonger la durée des brevets sur la base des études en cours de la FDA et à exploiter la licence de la technologie de bioréacteur automatisé de l’entreprise pour réduire les coûts de production et améliorer l’accès aux traitements.
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) hat eine Partnerschaft mit PatentVest, einer Tochtergesellschaft von MDB Capital, geschlossen, um sein globales Patentportfolio im Bereich der autologen Stammzelltherapie für Herz-Kreislauf-Erkrankungen zu stärken. PatentVest wird umfassende Unterstützung im Bereich geistiges Eigentum bieten, einschließlich:
- Bewertung und Optimierung bestehender Patente
- Identifikation neuer patentierbarer therapeutischer Innovationen
- Entwicklung globaler Anmeldestrategien
- Steigerung des Unternehmenswerts für strategische Partnerschaften
PatentVest akzeptiert eine teilweise Zahlung in Form von Aktien, um die Interessen der Aktionäre zu berücksichtigen. Die Partnerschaft zielt darauf ab, die Patentlaufzeiten basierend auf laufenden FDA-Studien zu verlängern und die Lizenz der automatisierten Bioreaktortechnologie des Unternehmens zu nutzen, um Produktionskosten zu senken und die Zugänglichkeit der Behandlung zu verbessern.
- Patent terms may be extended based on ongoing FDA studies
- Automated bioreactor technology license to reduce production costs
- PatentVest accepting partial payment in equity, aligning with shareholder interests
- Strategic positioning for improved licensing opportunities and premium valuations
- None.
Calgary, Alberta--(Newsfile Corp. - April 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) a leader in the development of autologous stem cell therapy for the treatment of cardiovascular diseases, announces its partnership with PatentVest.
PatentVest, a subsidiary of MDB Capital (NASDAQ: MDBH), is a premier intellectual property strategy and patent prosecution firm specializing in life sciences.
The engagement underscores Hemostemix's commitment to expanding its intellectual property portfolio to drive innovation and shareholder value. PatentVest will provide Hemostemix with a comprehensive strategic intellectual property support program, including:
Evaluating and optimizing Hemostemix's existing patent portfolio to ensure alignment with R&D and commercialization objectives.
Identifying and securing patentable claims for new therapeutic innovations.
Developing and executing global filing strategies to strengthen Hemostemix's IP footprint in key markets.
Enhancing the company's value by positioning it to attract strategic partners, expand licensing opportunities, and command premium valuations in the biotechnology sector.
"Our collaboration with PatentVest is a strategic step forward to secure additional intellectual property rights and amplify the value of our existing patents" stated Thomas Smeenk, CEO, Hemostemix. "PatentVest is accepting partial payment in equity, which aligns its incentives with the long-term success of Hemostemix shareholders. This collaboration unlocks the full potential of our innovations and maximizes our market opportunities," Smeenk said.
Will Rosellini, Chief Intellectual Property Officer of PatentVest, commented: "By applying our time-tested Leadership Development Process to build upon the Company's meaningful IP portfolio, Hemostemix will be well-positioned with a strong, defensible position in scalable autologous stem cell treatments for cardiovascular diseases. We are exploring opportunities to extend the terms of Hemostemix's patents based on its ongoing FDA studies, potentially prolonging market exclusivity for its groundbreaking therapies. Additionally, Hemostemix's license of the automated bioreactor technology promises to significantly reduce production costs, making treatments more accessible and scalable. This partnership strengthens Hemostemix's IP strategy, and positions the company to transform cardiovascular treatment affordability and drive exponential shareholder value," Rosellini added.
About PatentVest
PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is the first integrated IP intelligence, strategy, and law firm that enables visionary companies to develop into technology leaders. By combining our proprietary database with our proven IP diligence process and expert analysis, we deliver actionable insights on the IP landscape to help our clients make informed decisions and stay ahead of the curve. The trends and competitive insights in this report are powered by PatentVest's proprietary IP intelligence platform. Our reports keep a pulse on the key players, technologies, and opportunities shaping deep technology markets.
About Hemostemix
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of
Learn more: www.hemostemix.com
Contact: Thomas Smeenk, President & CEO (905) 580-4170
Email: tsmeenk@hemostemix.com |
Stock Information: TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0 |
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: Patentvest and Hemostemix working together to generate new intellectual property and value for Hemostemix shareholders, the sale of ACP-01 as a treatment for cardiovascular diseases including vascular dementia, and the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression;the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/249528
FAQ
What is the purpose of Hemostemix's partnership with PatentVest for HMTXF stock?
How will PatentVest be compensated for their services to HMTXF?
What potential benefits does the PatentVest partnership bring to HMTXF investors?
How will the automated bioreactor technology impact HMTXF's business model?
